Salud financiera de hoja de balance de Egetis Therapeutics

Salud financiera controles de criterios 4/6

Egetis Therapeutics tiene un patrimonio de los accionistas total de SEK545.6M y una deuda total de SEK108.6M, lo que sitúa su ratio deuda-patrimonio en 19.9%. Sus activos y pasivos totales son SEK760.2M y SEK214.6M respectivamente.

Información clave

19.9%

Ratio deuda-patrimonio

kr108.60m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr303.30m
Patrimonio	kr545.60m
Total pasivo	kr214.60m
Activos totales	kr760.20m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Dec 21

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Jun 07

Recent updates

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Mar 22

What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 15

What You Need To Know About Egetis Therapeutics AB (publ)'s (STO:EGTX) Investor Composition

Jan 20

Egetis Therapeutics AB (publ) (STO:EGTX) Insiders Increased Their Holdings

Dec 24

Analyst Forecasts For PledPharma AB (publ) (STO:PLED) Are Surging Higher

Dec 03

When Will PledPharma AB (publ) (STO:PLED) Breakeven?

Dec 03

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK345.9M) de EGTX superan a sus pasivos a corto plazo (SEK103.9M).

Pasivo a largo plazo: Los activos a corto plazo de EGTX (SEK345.9M) superan a sus pasivos a largo plazo (SEK110.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: EGTX tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de EGTX ha crecido de 0% a 19.9% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: EGTX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: EGTX tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 22.6% cada año

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Egetis Therapeutics

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

PledPharma to Be Deleted from Other OTC

Recent updates

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Share price stability

Price target increased by 11% to kr12.30

Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency

Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency

Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial

Chief Executive Officer recently bought kr61k worth of stock

Price target decreased by 8.3% to kr13.30

Forecast breakeven date pushed back to 2025

Independent Director recently bought kr206k worth of stock

Director recently bought kr992k worth of stock

Consensus revenue estimates decrease by 14%, EPS upgraded

Price target decreased by 7.4% to kr14.50

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

Egetis Terminates Discussions Regarding Potential Acquisition

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 13% to kr17.75

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 16%

Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021)

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Consensus EPS estimates fall by 15%

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Egetis Therapeutics AB Submits Expanded Access Program for Emcitate® in the USA

Egetis Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Egetis Therapeutics AB (publ) Receives Positive Opinion on Orphan Designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

Forecast breakeven date pushed back to 2024

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

No longer forecast to breakeven

Egetis Therapeutics AB (Publ) Announces Executive Changes

Price target decreased to kr9.00

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Egetis Therapeutics AB (Publ) Announces That the Recruitment Target Has Been Met in the Emcitate® Triac Trial II Study

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) Secures Conditional Acceptance for Emcitate® as Brand Name in the US

Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Egetis Therapeutics AB (publ) Concludes Demonstrating Treatment Effects on T3 Levels in Mct8-Deficiency Could Provide Basis for Marketing Approval for Emcitate® in the Us

Egetis Therapeutics AB (Publ) Gets Notice of Intent to Grant for a New European Patent for a Combination Therapy with Aladote

Egetis Therapeutics AB (publ) Intends to Submit Marketing Authorisation Application for Emcitate® to the European Medicines Agency Based on Existing Clinical Data

Chief Executive Officer recently bought kr299k worth of stock

Third quarter 2021 earnings released: kr0.14 loss per share (vs kr0.46 loss in 3Q 2020)

Chief Financial Officer recently bought kr210k worth of stock

Egetis Receives Approval in Turkey for Compassionate Use of Emcitate® for MCT8 Deficiency

Chief Executive Officer recently bought kr55k worth of stock

Insider recently bought kr167k worth of stock

Second quarter 2021 earnings released: kr0.21 loss per share (vs kr0.68 loss in 2Q 2020)

Insider recently bought kr197k worth of stock

No longer forecast to breakeven

Insider recently bought kr183k worth of stock

Insider recently bought kr188k worth of stock

First quarter 2021 earnings released: kr0.12 loss per share (vs kr0.80 loss in 1Q 2020)

Full year 2020 earnings released: kr2.66 loss per share (vs kr1.19 loss in FY 2019)

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Analysts update estimates